ECSP22057865A - Inhibidores de formas mutantes de egfr - Google Patents

Inhibidores de formas mutantes de egfr

Info

Publication number
ECSP22057865A
ECSP22057865A ECSENADI202257865A ECDI202257865A ECSP22057865A EC SP22057865 A ECSP22057865 A EC SP22057865A EC SENADI202257865 A ECSENADI202257865 A EC SENADI202257865A EC DI202257865 A ECDI202257865 A EC DI202257865A EC SP22057865 A ECSP22057865 A EC SP22057865A
Authority
EC
Ecuador
Prior art keywords
inhibitors
egfr mutants
egfr
mutants
useful
Prior art date
Application number
ECSENADI202257865A
Other languages
English (en)
Inventor
Brett Williams
Kevin Wilson
Savi Christopher De
Thomas Dineen
Natasja Brooijmans
Joseph Kim
Aysegul Ozen
Emanuele Perola
John Campbell
Douglas Wilson
Meredith Eno
Jason Brubaker
Original Assignee
Blueprint Medicines Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blueprint Medicines Corp filed Critical Blueprint Medicines Corp
Publication of ECSP22057865A publication Critical patent/ECSP22057865A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente divulgación proporciona un compuesto representado por la fórmula estructural (I): o una sal farmacéuticamente aceptable de este útil para tratar un cáncer.
ECSENADI202257865A 2019-12-23 2022-07-22 Inhibidores de formas mutantes de egfr ECSP22057865A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962953030P 2019-12-23 2019-12-23

Publications (1)

Publication Number Publication Date
ECSP22057865A true ECSP22057865A (es) 2022-11-30

Family

ID=74186977

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202257865A ECSP22057865A (es) 2019-12-23 2022-07-22 Inhibidores de formas mutantes de egfr

Country Status (19)

Country Link
US (2) US20230056541A1 (es)
EP (1) EP4081515A1 (es)
JP (1) JP2023508976A (es)
KR (1) KR20230005112A (es)
CN (1) CN115135642A (es)
AR (1) AR121044A1 (es)
AU (1) AU2020412710A1 (es)
BR (1) BR112022012585A2 (es)
CA (1) CA3163007A1 (es)
CL (1) CL2022001731A1 (es)
CO (1) CO2022010317A2 (es)
CR (1) CR20220354A (es)
EC (1) ECSP22057865A (es)
IL (1) IL294251A (es)
MX (1) MX2022007969A (es)
PE (1) PE20221264A1 (es)
TW (1) TW202138364A (es)
UY (1) UY39002A (es)
WO (1) WO2021133809A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220354A (es) * 2019-12-23 2022-12-19 Blueprint Medicines Corp Inhibidores de egfr
CN115279771A (zh) 2020-01-15 2022-11-01 缆图药品公司 Map4k1抑制剂
EP4304727A1 (en) 2021-03-10 2024-01-17 Blueprint Medicines Corporation Egfr inhibitors
EP4359401A1 (en) * 2021-06-23 2024-05-01 Blueprint Medicines Corporation Process for preparing egfr inhibitors
CA3223859A1 (en) * 2021-06-23 2022-12-29 Erika BUTLER Salt and crystal forms of an epidermal growth factor receptor inhibitor
WO2023283130A1 (en) * 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
WO2023288264A1 (en) * 2021-07-15 2023-01-19 Blueprint Medicines Corporation Map4k1 inhibitors
CN115724827A (zh) * 2021-08-27 2023-03-03 上海翰森生物医药科技有限公司 稠环类衍生物抑制剂、其制备方法和应用
WO2023071998A1 (zh) * 2021-10-26 2023-05-04 杭州德睿智药科技有限公司 新型嘧啶或三嗪取代吡啶并杂环化合物
CN116159062A (zh) * 2021-11-24 2023-05-26 上海艾力斯医药科技股份有限公司 药物组合物及其用途
WO2023134266A1 (zh) * 2022-01-17 2023-07-20 苏州浦合医药科技有限公司 2-哌啶基或2-吡唑基取代的嘧啶化合物作为egfr抑制剂
TW202400579A (zh) * 2022-03-17 2024-01-01 大陸商上海翰森生物醫藥科技有限公司 含氮雜環類衍生物抑制劑、其製備方法和應用
TW202406552A (zh) 2022-03-22 2024-02-16 美商纜圖藥品公司 用於治療癌症之ｅｇｆｒ抑制劑
TW202404590A (zh) 2022-04-05 2024-02-01 美商纜圖藥品公司 Ｅｇｆｒ抑制劑
WO2023241618A1 (zh) * 2022-06-14 2023-12-21 南京明德新药研发有限公司 氨基嘧啶类化合物及其应用
WO2024008048A1 (zh) * 2022-07-04 2024-01-11 杭州德睿智药科技有限公司 新型嘧啶或三嗪取代吡啶并杂环化合物
WO2024059169A1 (en) 2022-09-14 2024-03-21 Blueprint Medicines Corporation Egfr inhibitors
CN115650958B (zh) * 2022-10-14 2024-05-17 中国药科大学 2-氨基嘧啶类化合物及其制备方法、用途和药物组合物
CN115626939B (zh) * 2022-12-01 2023-06-16 北京鑫开元医药科技有限公司 一种egfr降解剂、制备方法、药物组合物及其应用
CN116969923A (zh) * 2023-01-18 2023-10-31 北京鞍石生物科技有限责任公司 杂芳基氨基化合物及其制备方法和应用
CN115974845A (zh) * 2023-01-19 2023-04-18 奥锐特药业股份有限公司 奥希替尼中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130225528A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
US9657009B2 (en) 2012-11-08 2017-05-23 Bristol-Myers Squibb Company Heteroaryl substituted pyridyl compounds useful as kinase modulators
JP6430390B2 (ja) 2012-11-20 2018-11-28 ジェネンテック， インコーポレイテッド Ｔ７９０ｍを含むｅｇｆｒ変異体の阻害剤としてのアミノピリミジン化合物
EP3052494B1 (en) * 2013-06-28 2018-12-26 H. Hoffnabb-La Roche Ag Azaindazole compounds as inhibitors of t790m containing egfr mutants
DK3429591T3 (da) 2016-03-16 2023-06-19 Kura Oncology Inc Substituerede thieno[2,3-D]pyrimidin-derivater som inhibitorer af Menin-MLL og fremgangsmåder til anvendelse
JP2020514388A (ja) 2017-03-24 2020-05-21 クラ オンコロジー，インク． 血液悪性腫瘍およびユーイング肉腫を処置するための方法
WO2020073945A1 (zh) 2018-10-10 2020-04-16 江苏豪森药业集团有限公司 双环类衍生物抑制剂、其制备方法和应用
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
CR20220354A (es) * 2019-12-23 2022-12-19 Blueprint Medicines Corp Inhibidores de egfr
CN115279771A (zh) 2020-01-15 2022-11-01 缆图药品公司 Map4k1抑制剂

Also Published As

Publication number Publication date
IL294251A (en) 2022-08-01
UY39002A (es) 2021-07-30
JP2023508976A (ja) 2023-03-06
CR20220354A (es) 2022-12-19
US11718602B2 (en) 2023-08-08
EP4081515A1 (en) 2022-11-02
BR112022012585A2 (pt) 2022-09-27
AU2020412710A1 (en) 2022-08-11
CA3163007A1 (en) 2021-07-01
CO2022010317A2 (es) 2022-10-21
CL2022001731A1 (es) 2023-07-14
WO2021133809A1 (en) 2021-07-01
MX2022007969A (es) 2022-12-13
PE20221264A1 (es) 2022-08-16
CN115135642A (zh) 2022-09-30
KR20230005112A (ko) 2023-01-09
US20230026209A1 (en) 2023-01-26
US20230056541A1 (en) 2023-02-23
TW202138364A (zh) 2021-10-16
AR121044A1 (es) 2022-04-13

Similar Documents

Publication Publication Date Title
ECSP22057865A (es) Inhibidores de formas mutantes de egfr
CO2021016504A2 (es) Inhibidores de cdk
CO2022004686A2 (es) Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo
CR20190124A (es) Inhibidores de ssao de aminopirimidina
UY38057A (es) Inhibidores de sarcómero cardíaco
MX2023000025A (es) Inhibidores de la quinasa progenitora hematopoyética 1 y usos de estos.
AR111304A1 (es) Métodos para sintetizar un inhibidor de mcl-1
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
CL2020003219A1 (es) Compuestos
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
ECSP17054980A (es) Inhibidores selectivos de bace1
EA201792320A1 (ru) Способ лечения рака ингибитором пути stat3 и ингибитором киназы
UY37941A (es) Derivados de bencimidazol y sus usos
MX2021011753A (es) Degradadores de moleculas peque?as de stat3.
CO2024000221A2 (es) Pirimidinil-pirazoles sustituidos como inhibidores de cdk2
DOP2023000280A (es) Inhibidores de cdk2
AR116951A1 (es) Sales cristalinas de un inhibidor de calicreína plasmática
PH12021550452A1 (en) Methods of treating mycobacterial infections using tetracycline compounds
EA202190989A1 (ru) Новый способ синтеза производных пиперазинил-этокси-бромфенила и их применение в получении содержащих их соединений
MX2020011991A (es) Inhibidores de la oncoproteina ras, metodos de produccion y metodos de uso de los mismos.
CO2021017202A2 (es) Compuestos tricíclicos
WO2018005444A3 (en) Methods for treating cancer
UY39662A (es) Inhibidores de egfr
AR126196A1 (es) Proceso para preparar inhibidores de egfr
CO2022008127A2 (es) Procesos e intermediario para la preparación de oxetan-2-ilmetanamina